8OHdG is not a biomarker for Huntington disease state or progression
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate plasma 8-hydroxy-deoxy-guanosine (8OHdG) levels as a potential biomarker of premanifest and early Huntington disease (HD). METHODS: Personnel from 2 independent laboratories quantified 8OHdG in blinded longitudinal plasma samples taken 24 months apart from 160 TRACK-HD participants, as well as samples containing control plasma with added ("spiked") 8OHdG. One laboratory used a liquid chromatography-electrochemical array (LCECA) assay, and the other used liquid chromatography-mass spectrometry (LCMS). RESULTS: The LCMS assay was more accurate than the LCECA assay for measurements of "spiked" 8OHdG levels in plasma. Neither assay demonstrated cross-sectional differences in plasma 8OHdG among controls, premanifest HD, and early symptomatic HD. Similarly, neither assay showed longitudinal changes in any disease group over 24 months. CONCLUSIONS: Plasma concentration of 8OHdG is not a biomarker of disease state or progression in HD. We recommend that future putative biomarker studies use blinded sample analysis, standard curves, independent analytical methods, and strict quality control of sample collection and storage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tabrizi, S. J., Langbehn, D. R., Leavitt, B. R., Roos, R. A., Durr, A., Craufurd, D., Kennard, C., Hicks, S. L., Fox, N. C., Scahill, R. I., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70170-x · Cited by 984 · cited 2×
“The present study used plasma samples from TRACK-HD, which employed a stringent, consistent sample collection and preparation protocol with quality-control measures and did not include a freezethaw cycle.(6)We also included plasma spiked with various concentrations of 8OHdG to ensure the assays were measuring the same…”
MethodSelf-citationBrowne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Urinary 8-hydroxy-2'-deoxyguanosine as a biological marker of in vivo oxidative DNA damage.
Shigenaga, M. K., Gimeno, C. J., & Ames, B. N. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.9697 · Cited by 732 · cited 1×
“8OHdG is a product of the oxidation of guanine by reactive oxygen species, and its levels in blood and urine may correlate with the degree of oxidative DNA damage.(17,18) Although increased levels of 8OHdG have been reported in patients with HD and mouse models indicating such oxidative DNA damage, the role of such da…”
BackgroundRate of functional decline in Huntington’s disease
Marder, K., Zhao, H., Myers, R. H., Cudkowicz, M., Kayson, E., Kieburtz, K., Orme, C., Paulsen, J., Penney, J. B., Siemers, E., et al. (2000) · Neurology · doi:10.1212/wnl.54.2.452 · Cited by 362
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000194318.74946.b6 · Cited by 313 · cited 5×
“These previous reports came to different conclusions about the effects of HD status on 8OHdG levels at baseline and through disease progression.(16,21,22) These analyses were not blinded, used the same LCECA assay, and did not include calibration curves or standardized methods of collection, preparation, and storage.”
BackgroundResultInfluentialHuntington’s disease: Clinical presentation and treatment
Novak, M. J. U., & Tabrizi, S. J. (2011) · International Review of Neurobiology · doi:10.1016/b978-0-12-381328-2.00013-4 · Cited by 137
Self-citation
Cited by
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Self-citationHuntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016
Self-citationByrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30124-2 · Cited by 364
Self-citationPotential biomarkers to follow the progression and treatment response of Huntington’s disease
Disatnik, M.-H., Joshi, A. U., Saw, N. L., Shamloo, M., Leavitt, B. R., Qi, X., & Mochly-Rosen, D. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160776 · Cited by 58
“In a careful study on cohorts of presymptomatic and symptomatic HD patients (32 each), Borowsky et al. (2013) reported that plasma 8-OHdG was not found to be a biomarker of disease progression when using either liquid chromatography–mass spectrometry assay or liquid chromatography–electrochemical…”
MethodSelf-citation
Metadata
- Authors
- Borowsky, B., Warner, J., Leavitt, B. R., Tabrizi, S. J., Roos, R. A. C., Durr, A., Becker, C., Sampaio, C., Tobin, A. J., & Schulman, H.
- Venue
- Neurology
- Published
- 2013-05-21
- Volume
- 80
- Issue
- 21
- Pages
- 1934-1941
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2131685651
- Cited by
- 26
- References
- 6
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 8OHdG is not a biomarker for Huntington disease state or progression. https://app.cochat.ai/papers/10.1212/wnl.0b013e318293e1a1
- The paper
- Borowsky, B., Warner, J., Leavitt, B. R., Tabrizi, S. J., Roos, R. A. C., Durr, A., Becker, C., Sampaio, C., Tobin, A. J., & Schulman, H. (2013). 8OHdG is not a biomarker for Huntington disease state or progression. Neurology. https://doi.org/10.1212/wnl.0b013e318293e1a1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.